pembrolizumab
merck
['keynote189', 'nsclc', 'platinum', 'sclc', 'medsir']
 to on #keynote189 5y update: 1l pbo+pem-platinum vs pbo+pem-platinum continued to show improvement in os (mos: 22.0mo vs 10.6mo; 5-yos: 19.4% vs 11.3%) and pfs benefits (9.0mo vs 4.9mo), irrespective of pd-l1 expression in metastatic nonsquamous nsclc.
#esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM